References:
Alvar J, Canavate C, Gutierrez-Solar B, Jiminez M, Laguna F, Lopez-Velez R, Molina R, Moreno J. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev. 1997 Apr;10(2):298-319.

Araujo Z, El Bouhdidi A, Heremans H, Van March E, Castes M, Carlier Y. Vaccination of mice with a combination of BCG and killed Leishmania promastigotes reduces acute Trypanosoma cruzi infection by promoting INF-gamma response. Vaccine. 1999 Feb 26;17(7-8):957-64.

De-Luca PM, Mayrink W, Alves CR, Coutinho SG, Oliveira MP, Bertho AL, Toledo VP, Costa CA, Genaro O, Mendonsca SC. Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis. Vaccine. 1999 Mar 5;17(9-10):1179-85.

Gabaglia CR, Pederson B, Hitt M, Burdin N, Sercarz EE, Graham FL, Gauldie J, Braciak TA. A single intramuscular injection with adenovirus expressing IL-12 protects BALB/c mice against Leishmania major infection, while treatmentwith an IL-4 expressing vector increases disease susceptibility in B10.D2 mice. J Immunol. 1999 Jan 15;162(2):753-60.

Lee MB, Gilbert HM. Current Approaches to Leishmaniasis. Infect Med 1999;16(1):34,37-45. http://www.medscape.com/SCP/IIM/1999/v16.n01/m3148.lee/pnt-m3148.lee.html

Ohio State. Leishmania spp. http://www.biosci.ohio-state.edu/~parasite/leishmania.html

Paredes R, Laguna F, Bonaventura C. Leishmaniasis in HIV-infected persons: a review. Journal. Jun 1997. http://www.iapac.org/clinmgt/coindiseases/leishmaniasis.html

Sharifi I, FeKri AR, Aflatonian MR, Khamesipour A, Nadim A, Mousavi MR, Momeni AZ, Dowlati Y, Godal T, Zicker F, Smith PG, Modabber F. Randomized vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet. 1998 May 23;351(9115):1540-3.

The Special Programme for Research and Training in Tropical Diseases. Leishmaniasis. http://www.who.int/tdr/diseases/leish/default.htm

Spitzer N, Jardim A, Lippert D, Olafson RW. Long-term protection of mice against Leishmania major with a synthetic peptide vaccine. Vaccine. 1999 Mar 17;17(11-12):1298-300.

Tonui WK. Leishmania transmission-blocking vaccines: a review. East Afr Med J. 1999 Feb;76(2)93-6.

WHO. Leishmaniasis. Communicable Disease Surveillance and Response. http://www.who.int/emc/diseases/leish/leisgeo.html

WHO. The Leishmaniasis and Leishmaniasis/HIV co-infections. Fact Sheet #116. May 1996. http://www.who.int/inf-fs/en/fact116.html

Wolday D, Akuffo H, Fessahaye G, Valantine A, Britton S. Live and killed human immunodeficiency virus type-1 increases the intracellular growth of Leishmania donovani in monocyte-derived cells. Scand J Infect Dis. 1998;30(1):29-34.